RESPONSE TO IV LIDOCAINE PREDICT FAVORABLE RESPONSE TO ORAL MEXILETIE

飞行员患者于1997年7月28日入院并登记参加研究， 1997年7月30日出狱。从这次试行开始，按顺序进行了一些修改 以确保更顺畅的运行协议。已着手解决的问题 包括添加活性安慰剂，因为飞行员患者没有 难以确定研究的安慰剂阶段。这双倍的- 盲式交叉设计是一种改进，并获得了 JCCI。此外，还与调查药物管理局达成了安排 提供研究药物预先混合的服务，以确保 使我们的研究医生失明，并简化方案。这个 研究药物服务局提供了一份随机分组时间表， 也是。 已有四名输液患者跟随飞行员参与 在这项研究中(11月前共4项，共8项 到目前为止已完成)。病人继续登记加入邮局 截肢疼痛输液研究。

The Pilot patient was admitted and enrolled into the study 7/28/97 and discharged 7/30/97. From this pilot, some revisions took place in order to ensure a smoother running protocol. Issues that were worked on included the addition of an active placebo, as the pilot patient had no difficulty in identifying the placebo phase of the study. This double- blinded cross-over design was an improvement and was approved by the JCCI. Also, arrangements were made with the Investigational Drug Service to provide the study medications pre-mixed as to ensure the blinding of our study physician and to streamline the protocol. The Investigational Drug Service provided a block randomization schedule, as well. Four infusion patients have followed the pilot patient in participating in this study (a total of 4 prior to November, a total of 8 have been completed to date). Patients continue to be enrolled into the Post Amputation Pain Infusion Study.